Resistant Mycobacterium bovis Bacillus Calmette-Guérin Disease: Implications for Management of Bacillus Calmette-Guérin Disease in Human Immunodeficiency Virus-Infected Children

Pediatric Infectious Disease Journal

Volumn 23, Issue 5, 2004, Pages 476-479

  Hesseling, Anneke C ^a,c   Schaaf, Hendrik S ^a   Victor, Thomas ^b   Beyers, Nulda ^a   Marais, Ben J ^a   Cotton, Mark F ^a   Wiid, Ian ^b   Gie, Robert P ^a   Van Helden, Paul ^b   Warren, Robin M ^b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c Columbia University ^*  (United States)

Author keywords

Bacillus Calmette Gu rin; Human immunodeficiency virus; Management; Resistance

Indexed keywords

AMIKACIN; BCG VACCINE; CIPROFLOXACIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT;

ANTIBIOTIC SENSITIVITY; ARTICLE; AXILLARY LYMPH NODE; BACILLUS CALMETTE GUERIN DISEASE; BACTERIUM CULTURE; BCG VACCINATION; CASE REPORT; CODON; GENE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; INFANT; INFECTION; LYMPH NODE BIOPSY; MALE; MYCOBACTERIUM BOVIS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RPOB GENE; STOMACH SUCTION; VERTICAL TRANSMISSION;

ANIMALS; ANTITUBERCULAR AGENTS; BCG VACCINE; CATTLE; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, BACTERIAL; HIV INFECTIONS; HUMANS; INFANT; ISONIAZID; MUTATION; MYCOBACTERIUM BOVIS; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 2442629247     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000126593.21006.ac     Document Type: Article

References (24)

1. Lotte A, Wasz-Hockert O, Poisson N, et al. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc Lung Dis. 1988;63:47-59.
2. Talbot EA, Perkins MD, Silva SF, Frothingham R. Disseminated bacille Calmette-Guerin disease after vaccination: case report and review. Clin Infect Dis. 1997;24:1139-1146.
3. Hesseling AC, Schaaf HS, Hanekom WA, et al. Danish bacille Calmette-Guérin vaccine-induced disease in human immunodeficiency virus-infected children. Clin Infect Dis. 2003;37:1226-1233.
4. Schultz C, Kuijper EJ, van Soolingen D, Prins JM. Disseminated infection due to mulitdrug Mycobacterium bovis in a patient who was seropositive for human immunodeficiency virus. Clin Infect Dis. 1996; 23:841-843.
5. Valencia ME, Moreno V, Laguna F, Gonzalez-Lahoz JM. Multiresistant tuberculosis caused by Mycobacterium bovis and human immunodeficieny virus infection: are there new therapeutic modalities? Enferm Infecc Microbiol Clin. 2001;19:37-39.
6. Blazquez J, Espinosa de Los Monteros LE, Samper S, et al. Genetic characterization of multidrug-resistant Mycobacterium bovis strains from a hospital outbreak involving human immunodeficiency virus-positive patients. J Clin Microbiol. 1998;36:239-242.
7. Wayne LG. Microbiology of tubercle bacilli. Am Rev Respir Dis. 1982;125(suppl):31-41.
8. American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000; 161:1376-1395.
9. Parsons LM, Brosch R, Cole ST, et al. Rapid and simple approach for identification of Mycobacterium tuberculosis complex isolates by the PCR-based genomic deletion analysis. J Clin Microbiol. 2002;40:2339-2345.
10. Su WJ. Recent advances in the molecular diagnosis of tuberculosis. J Microbiol Immunol Infect. 2002;35:209-214.
11. Siddiqi SH. BACTEC 460 TB system. Product and procedure manual. Sparks, MD: Becton Dickinson; 1995.
12. Brosch R, Gordon S. V., Marmiesse M, et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci USA. 2002;99:3684-3689.
13. Talbot EA, Williams DL, Frothingham R. PCR identification of Mycobacterium bovis BCG. J Clin Microbiol. 1997;35:566-569.
14. Cousins DV, Skuce RA, Kazwala RR, van Embden JD. Towards a standardized approach to DNA fingerprinting of Mycobacterium bovis. International Union Against Tuberculosis and Lung Disease, Tuberculosis in Animals Subsection. Int J Tuberc Lung Dis. 1998;2:471-478.
15. Rastogi N, Goh KS, Berchel M, Bryskier A. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum. Mycobacterium bovis and M. bovis BCG. J Antimicrob Chemother. 2000;46:565-570.
16. Franzblau SG, Witzig RS, McLaughlin JC, et al. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J Clin Microbiol. 1998;36:362-366.
17. Wiid I, Hoal-van Helden E, Hon D, Lombard C, van Helden P. Potentiation of isoniazid activity against Mycobacterium tuberculosis by melatonin. Antimicrob Agents Chemother. 1999;43:975-977.
18. Musser JM. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev. 1995;8:496-514.
19. Musser JM, Kapur V, Williams DL, Kreiswirth BN, van Soolingen BN, van Embden FD. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J Infect Dis. 1996; 173:196-202.
20. Sicevic S. Generalized BCG tuberculosis with fatal course in two sisters. Acta Paediat Scand. 1972;61:178-184.
21. Berning SE, Huitt GA, Iseman MD, Peloquin CA. Malabsorption of antituberculous medications by a patient with AIDS. N Engl J Med. 1992;327:1817-1818.
22. Gutman LT, Moye J, Zimmer B, Tian C. Tuberculosis in human immunodeficiency virus-exposed or-infected United States children. Pediatr Infect Dis J. 1994; 13:963-968.
23. Nicol M, Eley B, Kibel M, Hussey G. Intradermal BCG vaccination: adverse reactions and their management. S Afr Med J. 2002;92:39-42.
24. Hengster P, Solder B, Fille M, Menardi G. Surgical treatment of bacillus Calmette Guérin lymphadenitis. World J Surg. 1997;21:520-523.